

18 January 2019

PolyNovo Limited ABN 96 083 866 862 2/320 Lorimer Street Port Melbourne

VIC Australia 3207

P +61 (0) 3 8681 4050 F +61 (0) 3 8681 4099

ASX Announcement

PolyNovo gains Malaysian regulatory approval

PolyNovo is pleased to announce the successful registration of NovoSorb BTM with the Medical Device Authority of Malaysia. This regulatory approval is the first of several Asian regulatory registrations anticipated.

Sales of NovoSorb BTM in Malaysia will occur only after the appointment of a distributer.

PolyNovo in discussion with a potential distributor for South East Asia.

CEO Paul Brennan said; "We are very excited to have achieved this regulatory approval ahead of the anticipated approval date. The Malaysian healthcare market is sophisticated, and we also foresee good opportunities for NovoSorb BTM in the region."

Chairman David Williams said; "The increasing sales in the US, Australia and New Zealand are very exciting, but the recent registration of BTM in India, Malaysia, Saudi, Israel and South Africa allow PolyNovo a new growth trajectory."

Further information,

Paul Brennan Chief Executive Officer Mobile, +61 427 662 317 David Williams Chairman

Mobile +61 414 383 593

About NovoSorb®

NovoSorb is a novel range of bio-resorbable polymers that can be produced in many formats including, film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and programmable bio-resorption profile.

About PolyNovo®

PolyNovo is an Australian based medical device company that designs, develops and manufactures dermal regeneration solutions (NovoSorb BTM) using its patented NovoSorb biodegradable polymer technology. Our development program covers Breast Sling, Hernia, and Orthopaedic applications. For further information and market presentations see www.polynovo.com.au